Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results

Showing results for

Understanding the molecular subtype of a cancer is becoming an importance part of the diagnostic process as it helps a doctor better understand a patient’s prognosis, determine the best course of action for treatment and helps researchers devise new, more-efficient, precision therapies.

Image information can be used to predict the molecular classification of patient tumour samples in colour, using state-of-the-art deep learning models in pathology

Chromosomal instability shapes the tumor microenvironment of esophageal adenocarcinoma via a cGAS-chemokine-myeloid axis.

Beernaert B. et al, (2026), Sci Adv, 12

HIF-1–regulated TPM3 links hypoxia to motility and invasion beyond the hypoxic fraction in triple-negative breast cancer

Zhou C. et al, (2026), npj Breast Cancer

Fully automated volumetry of ventricular subregions on computed tomography using object detection and semantic segmentation.

Da Mutten R. et al, (2026), Neuroimage Rep, 6

Photon FLASH spares radiation-induced changes in cardiac function, remodelling and arrythmia in a preclinical model.

Ghita-Pettigrew M. et al, (2026), Radiother Oncol, 216

HLA Heterozygosity Influences Colorectal Cancer Risk and Survival Outcome.

Tsai Y-Y. et al, (2026), Gastroenterology, 170, 619 - 622

DESTINY-Gastric05 phase III trial of first-line trastuzumab deruxtecan, chemotherapy, and pembrolizumab in HER2-positive gastric or gastroesophageal junction cancer

Janjigian YY. et al, (2026), ESMO Gastrointestinal Oncology, 11

0594 Drug-testing in patient-derived renal cell carcinoma organoids reveals pathways of vulnerability and resistance

Steven M. et al, (2026), European Urology, 89, S1 - S2

The PRAGMATIC pathway - PRostate cancer diAGnosis and MAnagement Triage In Clinical care.

Sharma A. et al, (2026), BJU Int

Protocol of the RADIO-STAR trial: a phase 1 safety and dose finding study of hypofractionated radiotherapy to the stellate ganglia for the treatment of ventricular arrhythmia.

Bussmann BM. et al, (2026), BMJ Open, 16

Is liquid biopsy a cost-effective method to diagnose Burkitt Lymphoma in children and young adults? A health economic evaluation in Tanzania.

Jiang J. et al, (2026), BMC Med

Real-time intraoperative depth estimation in transsphenoidal surgery using deep learning: A feasibility study.

Zanier O. et al, (2026), J Clin Neurosci, 147

ssessing the effects of a 3D pathology tissue-processing workflow on downstream molecular analyses.

Baraznenok E. et al, (2026)

CMS subtypes correlate with complete response in trial of neoadjuvant Galunisertib plus chemoradiation in rectal cancer.

Rajamanickam V. et al, (2026), Transl Oncol, 66

Negative Selection Maintains Grossly Altered but Broadly Stable Karyotypes in Metastatic Colorectal Cancer.

Cross WCH. et al, (2026), Cancer Discov, 16, 218 - 234

Succinate receptor 1 restricts hematopoiesis and prevents acute myeloid leukemia progression.

Cuminetti V. et al, (2026), Nat Commun

Characterisation of bacteria-induced colitis and its modulation by probiotics in naked mole rats: a new mammalian model for acute inflammatory disease.

Hart DW. et al, (2026), J Pathol

Shortened High-dose Palliative Radiotherapy for Lung Cancer (SHiP-Rt): protocol for a single-arm, multicentre, phase II study.

Shrimali RK. et al, (2026), BMJ Open, 16

Bridging the gaps in fibroblast activation protein targeted radionuclide therapy: a translational perspective.

Wu C. et al, (2026), Eur J Nucl Med Mol Imaging

Survival outcomes of ERBB2-amplified metastatic colorectal cancer treated with first-line chemotherapy.

Matsubara Y. et al, (2026), Br J Cancer, 134, 463 - 468

Media coverage and PATHFINDER2: hype, simplification, and free advertising.

Turnbull C. et al, (2026), Lancet Oncol, 27, 144 - 145

Load More

1
2
3
4
5
6
7
...
»